Atossa Genetics Hires Dr. Gerald Engley as Senior Director of Medical Affairs

SEATTLE, WA--(Marketwired - May 27, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that Dr. Gerald Engley has joined the Company as Senior Director of Medical Affairs, effective May 26, 2015. 

Steven C. Quay, M.D., Ph.D., President and CEO, commented, "Dr. Engley has over 20 years of pharmaceutical industry and managed care/hospital pharmacy experience at leading companies, including The Medicines Company, ZymoGenetics, A Bristol-Myers Squibb Company, and Berlex Laboratories. We look forward to Dr. Engley's contributions as we commercialize our medical devices and laboratory services, and as we develop pharmaceutical treatments for breast health conditions." 

Prior to joining Atossa, Dr. Engley was Senior Director, Global Health Science at The Medicines Company, focusing on development and execution of health science strategies, medical education review, promotional review, and development of formulary dossiers. He began his career in the pharmaceutical industry at Immunex Corporation and Berlex Laboratories focusing on medical information and medical communications. Dr. Engley then held the position of Senior Director, Medical Affairs at ZymoGenetics/Bristol-Myers Squibb and was responsible for field medical, medical information, medical communication, and pharmacoeconomics. Dr. Engley has received multiple individual awards, including the "Medical Achievement Award" (Bristol-Myers Squibb), and the "Circle of Excellence" and "Outstanding Medical Contribution" (ZymoGenetics) awards. Prior to his career in the pharmaceutical industry, he was a clinical pharmacist specializing in oncology and home infusion therapy at the Group Health Cooperative in Seattle, Washington. Dr. Engley received his Bachelor of Science in Pharmacy and Doctorate of Pharmacy degrees from the University of Washington, in Seattle, Washington.

On May 26, 2015, and as an inducement to cause Dr. Engley to join the Company, he was awarded an option to purchase a total of 100,000 shares of common stock of the Company, par value $0.001 per share, which are outside the Company's 2010 Stock Option and Incentive Plan but are subject to the terms of that plan. The stock option has an exercise price equal to $1.49 per share, the fair market value on the grant date and vests 25% at the end of the first year of employment and quarterly after that over the following three years of service. This stock option was granted as an inducement material to Dr. Engley entering into employment with the Company and is being reported in accordance with NASDAQ Listing Rule 5635(c)(4).

About Atossa Genetics
Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to achieve its objectives and continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch and commercialize in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Atossa does not undertake any obligation to update any forward-looking statement.